Stiefel has received FDA approval for Fabior Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years of age and older. The approval of Fabior Foam was based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies conducted in the US and Canada.
Fabior contains tazarotene, a retinoid in a topical foam formulation. While the mechanism of action is not clearly defined, the therapeutic effect of tazarotene in acne may be due to its anti-hyperproliferative, normalizing-of-differentiation and anti-inflammatory effects. Tazarotene is considered teratogenic and is therefore contraindicated during pregnancy. Females of childbearing potential should have a negative pregnancy test within two weeks prior to initiating treatment and use an effective method of contraception during treatment.
Fabior Foam will be supplied in 50g and 100g aluminum cans.
For more information call (888) 784-3335 or visit www.stiefel.com.